Also known as: 137525-51-0, Bpc 157, Bepecin, Bpc 15, L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-, pl-10, 8ED8NXK95P, PLD-116
BPC-157 (137525-51-0, Bpc 157, Bepecin) is classified under repair & thymosin peptides, sold for research use only and not approved for human consumption.
Aggregated from the cited literature below. We summarize sources — we don't author claims.
BPC-157 (body protection compound-157) is described as a stable gastric pentadecapeptide that has been investigated largely in preclinical models for effects related to cytoprotection and tissue repair across multiple organ systems, including musculoskeletal soft tissue and bone injuries. A systematic review from an orthopedic sports medicine perspective identified 36 included studies (35 preclinical, 1 clinical) reporting musculoskeletal improvements in multiple injury types, along with liver metabolism and kidney clearance; it also reported that no clinical safety data were found. (PMIDs: 40756949)
Mechanism (as reported)
Research reports that BPC-157 has been associated with effects on growth hormone receptor expression, pathways related to cell growth and angiogenesis, and reduced inflammatory cytokines in preclinical literature. (PMID: 40756949) Additional review material describes involvement of multiple molecular pathways in reported cytoprotective effects (including modulation of NO-system components and prostaglandin system effects) and activation of collateral pathways in vascular/ischemia-reperfusion contexts in animal studies. (PMID: 36359218) Another review describes gene-expression increases in rat excision skin wound as part of wound-healing research. (PMID: 34267654)
Key findings (each cites a source)
A systematic review reported that, across 35 preclinical studies and 1 clinical study, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injury models. (PMID: 40756949) [PMID 40756949]
The systematic review reported that the studies suggested BPC-157 enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis, and reduces inflammatory cytokines. (PMID: 40756949) [PMID 40756949]
The systematic review reported liver metabolism with a half-life of less than 30 minutes and clearance by the kidneys. (PMID: 40756949) [PMID 40756949]
The systematic review reported that preclinical safety studies showed no adverse effects across several organ systems and that no clinical safety data were found. (PMID: 40756949) [PMID 40756949]
A retrospective chart review reported that, among 12 patients receiving intra-articular BPC-157 alone for knee pain, 11 reported significant improvement and 1 reported no improvement; among 4 patients receiving BPC-157 combined with thymosin-beta-4, 75% showed significant improvement and 25% had no relief; overall, 14 of 16 reported relief. (PMID: 40005999) [PMID 40005999]
A narrative/biopharmaceutical review reported that no approved formulation and no validated dosing regimen were available, and that there were no completed Phase II clinical trials; it also described a disconnect between short plasma half-life reported in preclinical contexts and longer biological effects reported in the overall literature. (PMID: 42198317) [PMID 42198317]
A narrative review of wound healing described that BPC-157 was reviewed as effective in skin wound healing in rat studies, with reported involvement in resolution of vessel constriction, platelet plug and fibrin mesh, and clot resolution. (PMID: 34267654) [PMID 34267654]
An additional review described an 'angiogenic effect' in healing models, stating that BPC-157 was consistently effective across multiple gastrointestinal tract injury models and that it improved tendon, ligament, and bone healing in the context of review comparisons. (PMID: 29998800) [PMID 29998800]
Vendor test rankings (20)
Vendors ranked by their independent third-party test grade for BPC-157, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.4% across 845 tests. Not our verdict.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · PMID 40756949
Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B · Current pharmaceutical design · 2018 · PMID 29998800
FAQ
What is BPC-157?
BPC-157 (137525-51-0, Bpc 157, Bepecin) is classified under repair & thymosin peptides, sold for research use only and not approved for human consumption. Research goals associated with it include recovery & tissue repair.
Is BPC-157 FDA-approved?
No. BPC-157 is sold for research use only and is not approved for human consumption.
What does the research on BPC-157 say?
peptideone aggregates 8 references from PubMed for BPC-157. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.